ANONYMOUS: "Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS - Tabular View - ClinicalTrials.gov", 8 August 2014 (2014-08-08), XP055679718, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT02212886> [retrieved on 20200325] (B1)

JERRY S. WOLINSKY ET AL: "GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis", MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol. 4, no. 4, 1 July 2015 (2015-07-01), NL, pages 370 - 376, XP055473190, ISSN: 2211-0348, DOI: 10.1016/j.msard.2015.06.005 (B1)

TABANSKY INNA ET AL: "Advancing drug delivery systems for the treatment of multiple sclerosis", IMMUNOLOGIC RESEARCH, HUMANA PRESS, INC, US, vol. 63, no. 1, 16 October 2015 (2015-10-16), pages 58 - 69, XP035952355, ISSN: 0257-277X, [retrieved on 20151016], DOI: 10.1007/S12026-015-8719-0 (B1)

WO-A1-2018/042423 (B1)

US-A1- 2014 135 254 (B1)

WO-A1-2018/002930 (B1)

US-A1- 2012 015 891 (B1)